Survival Win With Inavolisib-Based Triplet in PIK3CA-Mutated Breast Cancer

By News Health
6 hours Ago

(MedPage Today) — CHICAGO — Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly improved survival in advanced breast cancer patients with PIK3CA-mutated, endocrine-resistant disease…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115726

Author :

Publish date : 2025-05-22 21:00:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

'My son could so easily have been another Nottingham killer'

FDA Panel Recommends Monovalent COVID Vaccine for Next Season

Study Links GLP-1 Drugs to Lower Cancer Risk

FDA Chief Defends Job Cuts, COVID Booster Policy at Senate Hearing

Prasugrel Strategy Rolls Short DAPT and De-Escalation Into One

FDA Approves Roflumilast Foam for Scalp, Body Psoriasis